Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Positive CHMP Opinion for Once-weekly Somatropin Biopartners

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
Approval of Somatropin Biopartners for the treatment of growth hormone deficiency in paediatric and adult patients.

Biopartners GmbH has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners for the treatment of growth hormone deficiency (GHD) in paediatric and adult patients.

The CHMP's recommendation is now referred to the European Commission (EC) which grants approval for the European Union, Norway and Iceland. The EC decision is anticipated in the middle of the third quarter of 2013.

Somatropin Biopartners is the first prolonged-release somatropin-containing medicinal product to receive a positive CHMP opinion.

Somatropin Biopartners will allow for a once-weekly subcutaneous injection instead of the currently available therapies that require once-daily injections of growth hormone (GH).

Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current GH replacement therapy in children as well as adults.

The typical symptom of GHD in children is growth failure, and consequently the aim of treatment is the normalization of the growth rate during childhood and attainment of normal adult height.

The clinical features associated with GHD in adults include abdominal obesity, decreased lean body mass, reduced muscle strength and exercise capacity, abnormalities in lipid and cardiovascular markers, decreased bone mineral density and impaired quality of life.

In Phase III comparative trials in children and adults, respectively, which were conducted as part of a joint development programme with LG Life Sciences Ltd., Somatropin Biopartners proved to be safe and effective, showing sustained growth in children and beneficial effects on body composition in adults.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos